|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.
TheStreet's Adam Feuerstein answers reader questions about biotech investing.
Click here to see latest analysisOncothyreon, Inc. reports financial results for the quarter ended March 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -12.89 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.ONTY-US‘s earnings and EBITDA are both […] (Read more...) The post Oncothyreon, Inc. :ONTY-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 appeared first on CapitalCube.